Journal of International Oncology››2018,Vol. 45››Issue (3): 157-160.doi:10.3760/cma.j.issn.1673-422X.2018.03.007
Previous ArticlesNext Articles
Wei Tiejun, Guo Yijing, Zhang Yongli, Jiang Meng, Zhang Heng
Received:
2017-08-23Online:
2018-03-08Published:
2018-05-16Contact:
Zhang Heng E-mail:2077388096@qq.comWei Tiejun, Guo Yijing, Zhang Yongli, Jiang Meng, Zhang Heng. Relationship between total serum IgG concentration and tumor progression in patients with gastric cancer[J]. Journal of International Oncology, 2018, 45(3): 157-160.
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30. DOI: 10.3322/caac.21332. [2] 宋杰, 陈凤格, 赵伟, 等. 胃癌的发病率现状与治疗研究进展[J]. 中国慢性病预防与控制, 2016, 24(9): 704707. DOI: 10.16386/j.cjpccd.issn.1004-6194.2016.09.019. [3] Finn OJ. Cancer immunology[J]. N Engl J Med, 2008, 358(25): 2704-2715. DOI: 10.1056/NEJMra072739. [4] 郭振红, 曹雪涛. 肿瘤免疫细胞治疗的现状及展望[J]. 中国肿瘤生物治疗杂志, 2016, 23(2): 149-160. DOI: 10.3872/j.issn.1007-385X.2016.02.001. [5] 张百红, 岳红云. 免疫微环境促进肿瘤发生发展的机制研究进展[J]. 现代肿瘤医学, 2015, 23(6): 862-864. DOI: 10.3969/j.issn.1672-4992.2015.06.38. [6] Li Q, TeitzTennenbaum S, Donald EJ, et al. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy[J]. J Immunol, 2009, 183(5): 3195-3203. DOI: 10.4049/jimmunol.0803773. [7] Layke JC, Lopez PP. 胃癌: 诊断和治疗方案的选择[J]. 中国全科医学, 2015, 18(3): 248249. DOI: 10.3969/j.issn.10079572.2015.03.003. [8] Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation[J]. Semin Cancer Biol, 2017, 43: 74-89. DOI: 10.1016/j.semcancer.2017.03.001. [9] Kohrt HE, Tumeh PC, Benson D, et al. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immunooncology clinical trials[J]. J Immunother Cancer, 2016, 4: 15. DOI: 10.1186/s40425-016-0118-0. [10] 沈梦, 任秀宝. B淋巴细胞参与肿瘤免疫抑制机制的研究进展[J]. 中国肿瘤生物治疗杂志, 2016, 23(1): 135-139. DOI: 10.3872/j.issn.1007-385X.2016.01.023. [11] Karagiannis P, Gilbert AE, Josephs DH, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma[J]. J Clin Invest, 2013, 123(4): 1457-1474. DOI: 10.1172/JCI65579. [12] Mizukami M, Hanagiri T, Shigematsu Y, et al. Effect of IgG produced by tumorinfiltrating B lymphocytes on lung tumor growth[J]. Anticancer Res, 2006, 26(3A): 1827-1831. [13] Jefferis R, Kumararatne DS. Selective IgG subclass deficiency: quantification and clinical relevance[J]. Clinical & Experimental Immunology, 1990, 81(3): 357-367. [14] 蔡晓珊, 朱洪光, 牛娜. 免疫球蛋白G在牙龈鳞状细胞癌中的表达[J]. 山东医药, 2013, 53(29): 4-6. DOI: 10.3969/j.issn.1002-266X.2013.29.002. [15] 朱颖蔚, 岑岭, 王梦洁. 胃癌患者血清血管内皮生长因子、组织多肽特异性抗原的表达及意义[J]. 实用临床医药杂志, 2015, 19(15): 174-175. DOI: 10.7619 /jcmp.201515059. [16] Storm L, Christensen IJ, Jensenius JC, et al. Evaluation of complement proteins as screening markers for colorectal cancer[J]. Cancer Immunol Immunother, 2015, 64(1): 41-50. DOI: 10.1007/s00262-014-1615-y. [17] Coronella JA, Spier C, Welch M, et al. Antigendriven oligoclonal expansion of tumorinfiltrating B cells in infiltrating ductal carcinoma of the breast[J]. J Immunol, 2002, 169(4): 1829-1836. [18] Guillem EB, Sampsel JW. Antitumorassociated antigens IgGs: dual positive and negative potential effects for cancer therapy[J]. Adv Exp Med Biol, 2006, 587: 341-374. [19] Inoue S, Leitner WW, Golding B, et al. Inhibitory effects of B cells on antitumor immunity[J]. Cancer Res, 2006, 66(15): 7741-7747. DOI: 10.1158/00085472.CAN-05-3766. [20] DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer[J]. Ann N Y Acad Sci, 2010, 1183: 38-57. DOI: 10.1111/j.1749-6632.2009.05137.x. [21] Nelson BH. CD20+ B cells: the other tumorinfiltrating lymphocytes[J]. J Immunol, 2010, 185(9): 4977-4982. DOI: 10.4049/jimmunol.1001323. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[5] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[6] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[7] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[8] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[9] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[10] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[11] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[12] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[13] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[14] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[15] | Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||